Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Payables (2016 - 2025)

Neurocrine Biosciences' Payables history spans 16 years, with the latest figure at $674.3 million for Q4 2025.

  • For Q4 2025, Payables rose 46.08% year-over-year to $674.3 million; the TTM value through Dec 2025 reached $674.3 million, up 46.08%, while the annual FY2025 figure was $674.3 million, 46.08% up from the prior year.
  • Payables reached $674.3 million in Q4 2025 per NBIX's latest filing, up from $584.3 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $674.3 million in Q4 2025 to a low of $171.9 million in Q1 2021.
  • Average Payables over 5 years is $374.7 million, with a median of $375.0 million recorded in 2023.
  • Peak YoY movement for Payables: soared 68.91% in 2023, then fell 21.93% in 2024.
  • A 5-year view of Payables shows it stood at $225.8 million in 2021, then skyrocketed by 53.94% to $347.6 million in 2022, then rose by 29.11% to $448.8 million in 2023, then increased by 2.85% to $461.6 million in 2024, then skyrocketed by 46.08% to $674.3 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Payables are $674.3 million (Q4 2025), $584.3 million (Q3 2025), and $489.5 million (Q2 2025).